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I.  INTRODUCTION 
Two million Americans suffer from limb loss.1  If the status quo persists, 
experts estimate this number will double in the next four decades.2  For the 
fortunate, a prosthetic limb, or the “artificial substitute or replacement of a part 
of the body . . .” is oftentimes available.3 Modern science has created 
prosthetics for all arrays of body parts including fingers, hands, arms, legs, and 
feet.4  Recently, the advent of new plastics and materials has “allowed artificial 
limbs to be stronger and lighter, limiting the amount of extra energy necessary 
to operate the limb.”5  Despite scientific ingenuity and monumental strides in 
research, amputees face far more than just physical pain.6 
A.  A GROWING FIELD 
The practice of Orthotics and Prosthetics (O&P) is working to restore 
Americans with mobility and independence, and has undergone tremendous 
growth in recent years.7  Just two decades ago, the field was widely considered a 
“trade” in which budding prosthetists and orthotists shadowed senior 
practitioners.8  Much like the legal profession however, which moved from 
apprenticeships to a nationally standardized curriculum and rules under the 
American Bar Association, the O&P field has enlarged and become more 
demanding of prospective practitioners.9   
The National Commission on Orthotic and Prosthetic Education (NCOPE) 
“develops, implements, and assures compliance with standards for orthotic and 
prosthetic education through accreditation and approval processes that promote 
exemplary patient care.”10  In order to become fully licensed today, U.S. 
practitioners must receive a Master’s Degree from one of twelve accredited 
                                                                                                                   
 1 Limb Loss Statistics, AMPUTEE COALITION, http://www.amputee-coalition.org/limb-loss-reso 
urce-center/resources-by-topic/limb-loss-statistics/limb-loss-statistics/#1 (last visited Mar. 1, 2017). 
 2 Definition: Defining the Meaning of Prosthesis and Prosthetic, DISABLED WORLD, http://www.disab 
led-world.com/assistivedevices/prostheses/ (last visited Mar. 1, 2017). 
 3 Id.  
 4 Id.  
 5 Id.  
 6 Healthy Living for Amputees, WAR AMPS, http://www.waramps.ca/ways-we-help/living-with-
amputation/#Health (last visited Mar. 1, 2017).  
 7 Id. 
 8 Master of Science in Prosthetics and Orthotics, GEORGIA INSTITUTE OF TECHNOLOGY, http:// 
mspo.gatech.edu/the-program/ (last visited Mar. 1, 2017).  
 9 Accreditation Process, NATIONAL COMMISSION ON ORTHOTIC AND PROSTHETIC EDUCATION, 
http://ncope.org/accredited/process/ (last visited Mar. 1, 2017). 
 10 Mission, NATIONAL COMMISSION ON ORTHOTIC AND PROSTHETIC EDUCATION, http:// 
www.ncope.org/about/mission/ (last visited Mar. 1, 2017). 
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Masters of Science in Prosthetics and Orthotics (MSPO) programs, as well as 
complete a mandatory residency program in orthotics, prosthetics, or both.11 
Concurrent with the recent growth in O&P university programs has been 
the rise of technological development in the field.12  The high-tech, computer-
driven prostheses of today are a far cry from the earliest prototypes.13  The 
“Capua Leg” is considered to be the world’s first lower-extremity prosthetic, 
dating back to 300 BC Italy.14  Throughout the Renaissance, European 
practitioners increasingly experimented with prosthetic limb replacement and 
made great strides in the study of amputations.15  Global prosthetics then hit a 
new level of advancement as a direct result of the bloodiest war in American 
history.16  In four years of the Civil War, over 70,000 Americans lost limbs, a 
cruel side-effect of an insufficient knowledge of emergency medicine.17  
One of the earliest pioneers to enter the prosthetic industry was James 
Edward Hanger, a Confederate soldier who lost his own leg due to a 
cannonball.18  After the war, Hanger created J.E. Hanger & Company, and filed 
a series of patents as early as the 1880’s.19  Numbered U.S. Patent 951989,20 the 
first Hanger patent detailed the blueprint of a noiseless artificial foot that 
operated using pneumatic devices.21  
In 2016, Hanger Inc. was valued at over $1 Billion,22 and is “[t]he world’s 
premier provider of orthotic and prosthetic (O&P) services and products, 
offering the most advanced prosthetics and orthotics. . . .”23  While Hanger 
produces some of its own orthotic and prosthetic devices, it primarily depends 
on distribution companies for most of its high-end limbs.24  The distributors, 
                                                                                                                   
 11 Accredited Practitioner Programs, NATIONAL COMMISSION ON ORTHOTIC AND PROSTHETIC 
EDUCATION, http://www.ncope.org/accredited/practitioner/ (last visited Mar. 1, 2017).  
 12 Steve Brachmann, The Evolution of Prosthetic Devices: A Patent History, IPWATCHDOG (Dec. 1, 
2014), http://www.ipwatchdog.com/2014/12/01/the-evolution-of-prosthetic-devices-a-patent-
history/id=52227/.  
 13 Id.  
 14 Id.  
 15 Id.  
 16 Id.  
 17 Id.  
 18 The J.E. Hanger Story, HANGER, http://www.hanger.com/history/Pages/The-J.E.-Hanger-St 
ory.aspx (last viewed Mar. 1, 2017).  
 19 Id.  
 20 U.S. Patent No. 951989 (filed July 9, 1908). 
 21 Id.  
 22 Brachmann, supra note 12. 
 23 About Hanger, HANGER, http://www.hanger.com/about/Pages/default.aspx (last visited 
Mar. 1, 2017).  
 24 Products and Services, HANGER, http://www.hanger.com/about/Pages/Product-and-Services-
Business.aspx (last visited Mar. 1, 2017) (outlining Hanger Inc.’s primary business partnerships 
for O&P products and services). 
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including Southern Prosthetic Supply, move the products of some of the 
world’s largest component manufacturers.25  The component manufacturing 
groups are global behemoths, with just a few companies dominating the world-
wide market.26  
Ottobock is another one of the major players in the global prosthetic 
market.27  It was founded as a medical technology company in 1919, and in its 
nearly one-hundred-year history, the company has brought massive change to 
the industry.28  In 1997, Ottobock developed the C-Leg, “the world’s first fully 
microprocessor-controlled lower limb prosthesis system. . . .”29  This landmark 
invention was quickly followed by the above-knee prostheses, the X3.30  
Dubbed the “World’s most technologically advanced prosthetic leg,” the X3 is 
the product of a collaboration with the United States military.31 
B.  THE INSURANCE DEBACLE 
In the days following the 2013 Boston Marathon Bombing, fourteen people 
required amputations of limbs.32  Although prosthetic devices gave the 
survivors the chance to walk again, the costs of the limbs were staggering.33  
Today, a standard prosthetic leg can range from $5,000 to $50,000.34  Even 
worse than the initial cost is the fact that most legs need to be replaced after 
three to five years, and other componentry and gadgetry are often not included 
in the initial fitting.35 
Fortunately for many Boston Marathon survivors, Massachusetts required 
state residents to have health insurance, leaving an uninsured population of 
                                                                                                                   
 25 Supplier, SOUTHERN PROSTHETIC SUPPLY, http://www.spsco.com/by-supply-chain-partner. 
html (last visited Mar. 1, 2017).  
  26 Orthopaedic Prosthetics Market, PRNEWSWIRE (June 28, 2016, 1:56 PM), http://www.prnewsw 
ire.com/news-releases/orthopaedic-prosthetics-market-global-industry-analysis-and-opportunity-
assessment-2016-2026-300291508.html. 
 27 History, OTTOBOCK, http://www.ottobock.com/en/company/history/ (last visited Mar. 1, 
2017).  
 28 Id.  
 29 Id.  
 30 X3 Prosthetic Leg, OTTOBOCK, http://www.ottobockus.com/prosthetics/lower-limb-prosthe 
tics/solution-overview/x3-prosthetic-leg/ (last visited Mar. 1, 2017).  
 31 Id.  
 32 Gillian Mohney, Health Care Costs for Boston Marathon Amputees, ABC NEWS (Apr. 25, 2013), 
http://abcnews.go.com/Health/health-care-costs-boston-marathon-amputees-add-time/story?id 
=19035114.  
 33 Id.  
 34 Id.  
 35 Id.  
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approximately 3%.36  Many survivors were also graciously supported by public 
funding and donations following the catastrophe.37  
On the other hand, many other amputees rely on public insurance plans 
including Medicare.38  As the largest insurance provider in the United States, 
Medicare has approximately 150,000 amputees in its network.39  Currently, 
Medicare covers most prosthetic legs under Plan B.40  Also, like most private 
insurance companies, Medicare charges a 20% copay for covered devices.41  
There are pending federal legislature proposals, however, to the Medicare 
coverage scheme that many fear will limit access to top-of-the-line prosthetic 
devices.42  
If the new proposals are enacted, “Medicare would establish more stringent 
requirements to obtain advanced prosthetics, reduce the role of the prosthetist 
who creates and maintains prostheses, and eliminate some of the universal 
codes that all providers use to cover prosthetic care.”43  There is also the 
concern that these changes could stall research and development, because 
Medicare would likely refuse to cover more advanced and expensive 
technology.44  
Furthermore, Medicare could hamper patients’ ability to receive the best 
device for their mobility and lifestyle needs.45  According to a consumer report 
by Amputee-Coalition.org, a 2011 Office of the Inspector General report 
“concluded that Medicare inappropriately paid $43 million for lower-limb 
prosthetic claims that did not meet the established requirements for payment, 
such as missing information about the patient’s ability to walk or prosthetic 
devices that were medically unnecessary because the patient’s functional level 
did not correspond to the device delivered.”46  The same report also highlighted 
over $60 million in claims from patients who had no record of meeting with a 
referring doctor in the past half-decade.47  Medicare responded to the report by 
                                                                                                                   
 36 Id.  
 37 Id.  
 38 Medicare for People with Limb Loss, AMPUTEE COALITION (May 1, 2015), http://www.amputee-
coalition.org/resources/medicare-for-people-with-limb-loss/.  
 39 Nadia Kounang, Amputees Fight Medicare Proposal to Limit Prosthetics, CNN (Aug. 26, 2015, 5:13 
PM), http://www.cnn.com/2015/08/26/health/amputees-prosthetic-medicare-rule-change/.  
 40 Prosthetic Devices, MEDICARE.GOV, https://www.medicare.gov/coverage/prosthetic-devices. 
html (last visited Feb. 28, 2017).  
 41 Id.  
 42 Medicare for People with Limb Loss, supra note 38. 
 43 Kounang, supra note 39.  
 44 Id.  
 45 Medicare Coverage for Prosthetic Devices, AMPUTEE COALITION, http://www.amputee-coalition. 
org/medicare-coverage-for-prosthetic-devices/ (last visited Feb. 22, 2017).  
 46 Id.  
 47 Id.  
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asking its contractors who process Medicare claims to “more closely scrutinize 
what prosthetists submit.”48  Under this approach, Medicare has essentially 
sought to reduce prosthetist autonomy in favor of general medical 
practitioners.49  
Amputee-Coalition is an amputee advocacy group that is worried that these 
possible changes are going to create failures in the quality of health care and 
supply of necessary prosthetic devices.50  For instance, a prosthetist could fit a 
patient for a prosthesis that accurately fits their needs and activity level; 
however, if the medical doctor’s records differ from the prosthetist, and 
Medicare auditors catch the difference, they could go after the prosthetist for 
the cost of the device.51  Given this very possible conundrum, practitioners 
have “become increasingly concerned about delivering prosthetic devices to 
Medicare beneficiaries.”52  
Medicare currently uses “K-levels” to determine an “individual’s ability or 
potential to ambulate and navigate their environment.”53  According to the 
American Academy of Orthotists and Prosthetists, once a patient’s K-level is 
calculated, the prosthetist can determine what componentry is covered by 
Medicare.54  The lowest activity level is a K0, which means the patient “does 
not have the ability or potential to ambulate or transfer safely” and the patient 
would not be eligible for a prosthesis.55  On the other hand, a K4 means that 
the patient’s activity level exceeds basic skills and exhibits “high impact, stress, 
or energy levels,” and any ankle/foot prosthetic system is considered an 
appropriate product for them.56 
C.  A PUBLIC HEALTH CRISIS 
The combination of ever-increasing costs57 and proposed Medicare 
changes,58 along with the inaccuracies and discrepancies in fitting devices,59 has 
created a public health crisis in the United States.  An astonishing two million 
                                                                                                                   
 48 Id.  
 49 Id.  
 50 Id.  
 51 Id.  
 52 Id.  
 53 K-Levels, AMERICAN ACADEMY OF ORTHOTISTS AND PROSTHETISTS, http://www.oandp.org/ 
olc/course_extended_content.asp?frmCourseId=ACA066EC-443A-4822-822C-89BC1CBD684 
E&frmTermId=k-levels (last visited Jan. 5, 2017).  
 54 Id.  
 55 Id.  
 56 Id.  
 57 Mohney, supra note 32. 
 58 Kounang, supra note 39. 
 59 Medicare Coverage for Prosthetic Devices, supra note 45. 
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Americans live without a limb.60  The annual cost of health care services 
following limb amputations is $8.3 billion, even before the costs of prosthetic 
limbs and rehabilitative care.61 
In the U.S., approximately 54% of limb amputations are due to vascular 
issues, including diabetes and peripheral arterial disease.62  Trauma is the second 
most common cause of amputation at 45%.63  Unfortunately, amputations do 
not strike equally at all races and ethnicities, as black Americans are up to four 
times as likely to need amputations as whites.64  Also, due to America’s aging 
population, some studies have even estimated that the national amputation rate 
will increase by 50% in the next fifteen years, mostly due to increases in 
peripheral arterial disease.65 
Adrianne Haslet-Davis, a Boston Marathon bombing survivor, wants people 
to stop thinking about prosthetic legs as simply medical devices, and instead, 
realize that “these are human body parts.”66  For the nearly two million 
American’s living with limb loss, it can be a devastating condition that takes 
years to come back from.67  However, with support groups and the right 
prosthetist, amputees can oftentimes have almost the same life as before.68  
According to Haslet-Davis, the possible Medicare coverage changes are 
standing in the amputees’ way of their “human rights, to walk, dream, to be 
unstoppable.”69  Also arguably standing in amputees’ way is another driving 
force behind the high costs of prosthetic devices: Patents.70 
D.  PATENTS 
While patents issued before 1976 are searchable only by issue date, patent 
number, or current U.S classification, a post-1976 search for the terms 
                                                                                                                   
 60 Limb Loss Statistics, supra note 1. 
 61 Id.  
 62 Id. 
 63 Id.  
 64 Id.  
 65 Venkat Kalapatapu, Lower Extremity Amputation, UPTODATE (Jan. 21, 2016), http://www. 
uptodate.com/contents/lower-extremity-amputation.  
 66 Kounang, supra note 39. 
 67 Learning to Live as an Amputee, NPR (Apr. 22, 2013, 1:00 PM), http://www.npr.org/2013/ 
04/22/178436361/learning-to-live-as-an-amputee.  
 68 Id.  
 69 Kounang, supra note 39. 
 70 Timothy Holbrook, The Real Reason the EpiPen and Other Off-Patents are so Expensive, 
RAWSTORY (Aug. 25, 2016, 6:46 PM), http://www.rawstory.com/2016/08/the-real-reason-the-
epipen-and-other-off-patents-are-so-expensive/.  
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“prosthetic” and “limbs” still procures thousands of results.71  However, the 
patenting process in the O&P field is not limited to prosthetic limbs alone.  There 
are thousands of patents issued for prosthetic componentry, including liners, 
joints, sockets, feet, and air outlet valves.72  Given the high-tech investment in 
prosthetic limbs and related devices, it is no surprise that component 
manufacturers are willing to go the full mile to protect the fruits of their labor.73  
Ohio Willow Wood Company v. ALPS South offers a contemporaneous glimpse into 
high-stakes litigation regarding the alleged infringement of cushioning devices that 
fit over patients’ residual limbs.74  
Other medical-related fields demonstrate the influence patents have on 
prices in the market place.75  For instance, earlier this year, American consumers 
were enraged over the price of epinephrine pens, commonly called EpiPens.76  
These portable shots are used for the immediate relief of a severe allergic 
reaction, prompting many to rely on them daily.77  As such, the outrageous 
price increase became headline news, prompting law-makers and citizens alike 
to take action to reverse the health crisis created by the drug producers.78  The 
primary reason why Mylan, the pharmaceutical company behind the drug, was 
able to more than double the cost of the pen in just over three years, was due to 
their patent.79  Although now expired, the company maintains control over its 
exclusive generic version of the drug.80  This action by Mylan demonstrated a 
                                                                                                                   
 71 Search results for “prosthetic” and “limb” on U.S. Patent and Trademark Office Database, 
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetaht 
ml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=prosthetic&FIELD1=&co1=AND 
&TERM2=limb&FIELD2=&d=PTXT (follow hyperlink; then search both terms “prosthetic” and 
“limb”) (last visited Jan. 10, 2017). 
 72 Prosthetic Patents, ALPS SOUTH, http://www.easyliner.com/patents.php (last visited Mar. 19, 
2017). 
 73 Summary of Ohio Willow Wood Co. v. Alps S., LLC, 813 F.3d 1350 (Fed. Cir. 2016), U.S. 
PATENT AND TRADEMARK OFFICE, https://e-foia.uspto.gov/Foia/RetrievePdf?system=FCA&fl 
Nm=1-1l2_1 (last visited Mar. 19, 2017). 
 74 Id.  
 75 Jean O. Lanjouw, Patents, Price Controls, and Access to New Drugs, NATIONAL BUREAU OF 
ECONOMIC RESEARCH (May 2005), http://www.nber.org/papers/w11321. 
 76 Tara Parker-Pope & Rachel Rabkin Peachman, EpiPen Price Rise Sparks Concern for Allergy 
Sufferers, N.Y. TIMES: WELL (Aug. 22, 2016, 6:05 PM), http://well.blogs.nytimes.com/2016/08/ 
22/epipen-price-rise-sparks-concern-for-allergy-sufferers/?_r=0. 
 77 Id.  
 78 Id.  
 79 Andrew Pollack, Mylan Raised EpiPen’s Price Before the Expected Arrival of a Generic, N.Y. TIMES: 
BUS. DAY (Aug. 24, 2016), http://www.nytimes.com/2016/08/25/business/mylan-raised-epipe 
ns-price-before-the-expected-arrival-of-a-generic.html. 
 80 Id.  
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common strategy employed by patent-holding corporations—hiking the price 
just before the end of the patent’s life.81 
While prosthetic companies spend millions of dollars on costly litigation, 
many of the 185,000 Americans who undergo amputations each year82 cope 
with two main issues.  First, many struggle to ensure the limb that best fits their 
activity level is properly assigned to them by their practitioner.83  Second, many 
are unable to afford the limb, even with 80% covered by most private and 
public insurance plans.84   
E.  LICENSING 
Licensing is a legal shortcut to intellectual property law.85  Licensing 
schemes, whether compulsive or voluntary, can create beneficial contracts in 
which a patent owner’s permission is not required for use of their product, 
“provided that the user follows certain rules and pays fees set by law.”86  
Currently, compulsory licensing is found in a plethora of industries including 
cable, webcasting, and music contexts.87  In the copyright realm, a license is 
typically granted by sending notice to the holder of the copyright, along with a 
statutory fee that is set by the U.S Copyright Office.88  
In the patent universe, compulsory licensing is already deeply rooted in 
global agreements.89  Compulsory agreements have been recognized as “one of 
the flexibilities on patent protection included in the WTO’s90 [World Trade 
Organization] agreement on intellectual property. . . .”91  In 1995, the Trade-
Related Aspects of Intellectual Property Rights (TRIPS) Agreement took effect, 
following the completion of the 1994 Uruguay Round of WTO Discussions.92  
In the Agreement, member-states reached the general understanding that 
compulsory licensing would be used when generic copies of products, including 
pharmaceuticals, were to be produced for the domestic market, as opposed to 
                                                                                                                   
 81 Id.  
 82 Limb Loss Statistics, supra note 1. 
 83 Kounang, supra note 39. 
 84 Prosthetic Devices, supra note 40. 
 85 Rich Stim, Copyright and Compulsory Licenses, NOLO, http://www.nolo.com/legal-encyclop 
edia/copyright-compulsory-license.html (last visited Mar. 19, 2017). 
 86 Id.  
 87 Id.  
 88 Id.  
 89 Compulsory Licensing of Pharmaceuticals and TRIPS, WORLD TRADE ORGANIZATION (Sept. 
2006), https://www.wto.org/english/tratop_e/trips_e/public_health_faq_e.htm.  
 90 What is the WTO?, WORLD TRADE ORGANIZATION, https://www.wto.org/english/thewto 
_e/whatis_e/whatis_e.htm (last visited Mar. 19, 2017).  
 91 Id.  
 92 Id.  
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export.93  Furthermore, according to the WTO, a common misunderstanding 
was that the TRIPS Agreement was only applicable in emergency situations.94  
In reality, the WTO has stated that there is no specific or limited list of reasons 
for which a member-state may allow compulsory licensing.95  
However, the TRIPS Agreement did list a number of conditions that must 
be met for issuing compulsory licenses.  This includes the requirement that the 
group petitioning for a license “has to have tried to negotiate a voluntary 
license with the patent holder on reasonable commercial terms.”96  Moreover, it 
asserted that “the right holder shall be paid adequate remuneration in the 
circumstances of each case, taking into account the economic value of the 
authorization.”  
The TRIPS Agreement has been called “[a] step forward for international IP 
aficionados.”97  Even recently, however, the TRIPS Agreement’s language and 
intent have been contested in the U.S. federal courts as to their effect on 
imported products under patent protection.98  In the WTO’s Uruguay Round, it 
was also determined that the standard patent term in the United States was to 
be changed from seventeen years after the patent was granted to twenty years 
from the date of patent filings.99  This change extended the patent term for a 
number of industries including domestic pharmaceuticals.  
F.  LICENSING SCHEMES AS A LOW-RISK SOLUTION 
In the background section, this Note will dive into greater examination of 
current patents on prosthetics and associated components.  In highlighting this 
concern, patents held by the major global prosthetic componentry 
manufacturers will be examined, including Ottobock’s liners and prostheses.100  
The Note will also take a deeper look at the nature of patent protection, and the 
                                                                                                                   
 93 TRIPS and public health, WORLD TRADE ORGANIZATION, https://www.wto.org/english/trat 
op_e/trips_e/pharapatent_e.htm (last visited Mar. 19, 2017).  
 94 Id.  
 95 Id.  
 96 Id.  
 97 Daniel Gervais, TRIPS (and the TPP) make it to the Fed Circuit, TRIPSAGREEMENT.NET (Feb. 
13, 2016, 4:31 PM), http://www.tripsagreement.net/?p=551. 
 98 Id.  
 99 James Packard Love, Recent Examples of the Use of Compulsory Licenses on Patents, KNOWLEDGE 
ECOLOGY INTERNATIONAL (Mar. 31, 2007), http://www.keionline.org/misc-docs/recent_cls_8 
mar07.pdf. 
 100 See generally C-Leg Above Knee Prosthetic Leg, Ottobock, http://www.ottobockus.com/pro 
sthetics/lower-limb-prosthetics/solution-overview/c-leg-above-knee-system/ (last visited Mar. 1, 
2017).  
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unfortunate side-effects of such litigation, by analyzing the recent WillowWood 
patent infringement case.101 
Furthermore, two recent case studies will briefly be explored, in which 
compulsory licensing and voluntary licensing agreements were successfully 
implemented into problematic economic or health crises.  First, a case study on 
the licensing of HIV pharmaceuticals following the 2001 Doha Round of WTO 
trade negotiations will be analyzed.102  In this case, compulsory licensing was 
used to allow member-states to overcome patent obstacles to life-saving retro-
viral drugs in declared emergencies.103  A plethora of developing nations 
mandated the issuing of licenses in an “attempt to cut growing healthcare costs 
by encouraging the production and import of generic versions of the patented 
medicine.”104  Then, another case study will be examined in which a court 
granted Toyota a compulsory license on hybrid technologies created by Paice, 
LLC, which resulted in the companies settling on a voluntary license.105  
In the analysis section, the Note will examine the takeaways of the two case 
studies and go on to discuss both the pros and cons of licensing in the context of 
prosthetic limbs.  Several variations of patent licensing will be discussed, including 
compulsory and voluntary, and alternatives such as government investigative 
committees will be offered.  Finally, other options will also be analyzed as to their 
projected effect on prosthetic patentability and pricing, including 3-D printing 
and open sourcing.  The Note will finally advocate for legal and policy change to 
implement voluntary licensing-type practices to address the patent and 
cost/supply conundrum in the national prosthetic health crisis. 
G.  LIMITATIONS ON NOTE INQUIRY 
This Note recognizes several notable limitations to its inquiry.  First and 
foremost, it acknowledges that there are different insurance schemes which will 
undeniably affect the manner in which prosthetic limbs are chosen for patients, as 
well as the out-of-pocket expenses that the patient will have.  Although it will 
discuss Medicare as well as private insurance plans, the focal point of the Note is 
to examine the effect of licensing schemes on prosthetic cost and accessibility.  
                                                                                                                   
 101 See Ohio Willow Wood Co. v. Alps S., LLC, 843 F.3d 1350, 1361 (Fed. Cir. 2016).  
 102 See The Doha Round, WORLD TRADE ORGANIZATION, https://www.wto.org/english/tratop 
_e/dda_e/dda_e.htm (last visited Mar. 1, 2017).  
 103 See Thailand Issues Compulsory License for Patented AIDS Drug, INTERNATIONAL CENTER FOR 
TRADE AND SUSTAINABLE DEVELOPMENT (Dec. 13, 2006), https://www.ictsd.org/bridges-
news/bridges/news/thailand-issues-compulsory-licence-for-patented-aids-drug. 
 104 Id.  
 105 Love, supra note 99. 
11
Mumper: Limb Law: Licensing Solutions for the Prosthetic Industry's Paten
Published by Digital Commons @ Georgia Law, 2017
428 J. INTELL. PROP. L.  [Vol. 24:417 
 
Secondly, in addressing the prosthetic cost and patent crisis, the Note will 
only consider civilian patients in the United States.  While prosthetics are often 
considered in a military context, the Amputation System of Care (ASoC) 
program within the Department of Veterans Affairs is simply not applicable to 
the majority of Americans with limb loss.106  
Third, the Note concedes that while its primary goal is to posit opportunities 
to make prosthetic limbs more affordable in the U.S. domestic market, several 
of the component and limb manufacturers discussed are not American 
companies.107 
II.  BACKGROUND 
The O&P field currently patents not only prosthetic limbs in their entirety, 
but also specific componentry within.108  For instance, Ottobock holds patents 
on materials as simple as the “alignable coupling assembly for connecting two 
prosthetic limb components,” and as complex as entire micro-processor 
controlled knee joints.109  In 2015, Ottobock was granted Patent 9,192,488 for 
its “Liner for vacuum sockets, and use of the liner.”110  The patent describes the 
device as “[a] liner for receiving an amputation stump and for placement within 
a prosthetic vacuum socket.”111  
Similarly, WillowWood, an American competitor to German Ottobock, 
received a patent in February 2016 for its “Fabric covered polymeric prosthetic 
liner.”112  The patent, numbered 9,265,629, was described as “[a] prosthetic 
cushion liner and cushion locking liner for use as a standalone interface 
between an amputee’s residual limb and the interior of a prosthetic socket.”113  
                                                                                                                   
 106 See generally Amputation System of Care (ASoC), DEPARTMENT OF VETERANS AFFAIRS (June 10, 
2015), http://www.prosthetics.va.gov/asoc/index.asp. 
 107 See Mobility for People, OTTOBOCK, http://www.ottobock.com/en/company/ottobock-to 
day/ (last visited Mar. 1, 2017).  
 108 Search Results for “ottobock” and “prosthetic” on U.S. Patent and Trademark Office 
Database, http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=% 
2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=ottobock&FIELD1=&co1 
=AND &TERM2=prosthetic&FIELD2=&d=PTXT (follow hyperlink; then search both terms 
“ottobock” and “prosthetic”) (last visited Mar. 1, 2017). 
 109 Id.  
 110 Liner for vacuum sockets, and use of the liner, JUSTIA PATENTS (Nov. 12, 2008), http://patents. 
justia.com/patent/9192488.  
 111 Id.  
 112 Fabric Covered Polymeric Prosthetic Liner, Patent No. 9,265,629, U.S. PATENT AND TRADEMARK 
OFFICE (Feb. 23, 2016), http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOF 
F&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTX 
T&s1=9,265,629&OS=9,265,629&RS=9,265,629.  
 113 Id.  
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Just four years prior, WillowWood also received Patent Number 8,317,873 on 
the “Polymeric prosthetic liner with controlled stretch characteristics.”  
While those close to the industry may be able to denote these seemingly 
subtle differences between the aforementioned WillowWood patents, a 
layperson may not be able to.  This liberal patenting practice is nothing new for 
American prosthetic manufacturers.  The United States has dominated the 
world’s prosthetic patent-filing market in recent years.114  For instance, “Entities 
in the U.S. were granted 610 of the 810 prosthetic patents issued in the first half 
of 2015.”115  With these many patents, the U.S. prosthetic industry has also 
demonstrated it will fight tooth and nail to protect its products.116 
A.  CASE STUDY: THE OHIO WILLOW WOOD COMPANY V. ALPS SOUTH, LLC. 
Litigation between these two prosthetic manufacturers began in 2004 when 
The Ohio Willow Wood Company (OWW) charged Alps South, LLC (Alps) 
with infringement of U.S Patent No. 5,830,237 (hereby referred to as the ‘237 
patent).117  The patent for “Gel and Cushioning Devices,” was originally filed 
by OWW in 1996.118  According to the U.S. Patent and Trademark Office, the 
‘237 patent was described as “Articles of apparel for an amputee’s residuum and 
for non-amputees who desire or require padding or joint support.”119  
Specifically, these articles included a “cushion liner, cushion locking liner, open-
ended cushion knee or elbow sleeve and cushion flat sheet all useful for 
increasing the comfort of the wearer.”120  The purpose behind the liner was to 
provide suspension for prosthetic devices while also creating friction with the 
patient’s knee sleeve.121 
Following multiple reexaminations by the US Patent and Trademark Office 
(USPTO), the district court granted Alps’s motion for Summary Judgement “of 
invalidity as to all the asserted claims of the ‘237 patent.”122  However, 
throughout the patent reexamination stages, a claim was also brought against 
                                                                                                                   
 114 Medical Device Patents, MEDICAL ALLEY (Aug. 14, 2015), https://www.medicalalley.org/ 
media/16223/8_17_15_medical_device_patents_q1_q2_2015.pdf.  
 115 Id.  
 116 See Ohio Willow Wood Co. v. Alps S., LLC, 813 F.3d 1350, 1361 (Fed. Cir. 2016).  
 117 Id.   
 118 Gel and Cushioning Devices, Patent No. 5,830,237, U.S. PATENT AND TRADEMARK OFFICE (Nov. 3, 
1998), http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/neta 
html/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/5830237. 
 119 Id.  
 120 Id.  
 121 Id.  
 122 Ohio Willow Wood Co., 813 F.3d at 1354.  
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OWW for inequitable conduct.123  Specifically, the court found OWW’s 
attorney was in a position to correct misrepresentations he had made as to the 
submitted evidence.124  Due to unethical lawyering, the district court ruled the 
‘237 Patent to be unenforceable and demanded OWW pay a fine to Alps.125  
OWW appealed and in 2016 the case went before the U.S. Court of 
Appeals.126  During litigation, OWW argued about the physical characteristics of 
the liner in question, going so far as to compare the thickness of the 
materials.127  The Court also found the patent unenforceable for inequitable 
conduct in the second patent reexamination phase.128  According to IP Attorney 
Joshua Branson, “This case suggests that (1) in-house individuals who 
substantively participate in a USPTO proceeding on behalf of a patent owner 
may be held to the duty of candor even if a screen exists between the USPTO 
proceeding and litigation concerning the same patent. . . .”129  After twelve years 
of litigation, WillowWood lost the case and was forced to vacate its patent.130  
B.  CASE STUDY: THAILAND’S COMPULSORY LICENSING OF EFAVIRENZ 
In November 2006, Thailand’s government followed in the footsteps of 
Indonesia, Zambia, and a host of other developing nations, by allowing a 
compulsory license for Merck’s HIV drug, Efavirenz.131  The license was 
granted to encourage “the production and import of generic versions of the 
patented medicine.”132  Under the licensing agreement, the government’s 
Ministry of Public Health granted the Government Pharmaceutical 
Organization the right to legally create generic variations of Merck’s drug 
through the year 2011.133  The Thai government emphasized that the license 
met the WTO rules on generic production of medicines, “specifically citing the 
2001 Doha Declaration on the TRIPS Agreement and Public Health,” which 
permitted licenses in instances of emergency and public utility.134  The WTO’s 
                                                                                                                   
 123 Id. at 1354.  
 124 Id. at 1356. 
 125 Id. at 1357.  
 126 Id. at 1350. 
 127 Id. at 1358. 
 128 Id. at 1360.  
 129 Joshua Branson, Federal Circuit Upholds Inequitable Conduct Ruling in Ohio Willow Wood Company, 
BAKER HOSTETLER: IP INTELLIGENCE BLOG (May 14, 2016), https://www.ipintelligencereport. 
com/2016/03/14/federal-circuit-upholds-inequitable-conduct-ruling-in-ohio-willow-wood-compan 
y/.  
 130 Id.  
 131 Thailand Issues Compulsory License for Patented AIDS Drug, supra note 103.  
 132 Id.  
 133 Id.  
 134 Id.  
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TRIPS agreement enumerates that in such emergency cases, governments are 
not required to consult with the patent holder.135  
Not everyone was pleased with Thailand’s emergency declaration and 
subsequent acceptance of generics medication, however.136  Following the 
announcement, the American Chamber of Commerce in Thailand became an 
outspoken critic of the deal, stating that it would send a negative image to 
international investors.137  On the contrary, Médecins Sans Frontières138 offered 
praise for the licensing system, even calling for licensing to be expanded to 
other expensive and under-supplied drugs.139  While initially disappointed in the 
lack of notice from the Thai government, U.S.-based Merck stated it would 
“negotiate with the Thai government to agree on a ‘voluntary license’ for the 
generic production of efavirenz, or offer it a lower price for [the] drug.”140  
Despite differing takes on the emergency decision, the licensing provision 
set forth clear terms for the duration of its existence.141  First and foremost, the 
license was capped at supplying 200,000 people per year.142  Secondly, the Thai 
Government Pharmaceutical Organization stated it could “pay Merck a royalty 
fee of 0.5% of the total sale value of the imported or locally-produced 
generic.”143  The plan also called for the importation of an Indian-made 
efavirenz until Thailand’s generic manufacturers could begin their own 
sufficient production process.144 
However, following the notice of the government’s licensing plan, Merck 
vehemently rejected the 0.5% royalty figure.145  As negotiations fell through 
with Merck, other options presented themselves, including U.S.-based Abbott 
Laboratories.146  In early 2007, a compulsory license was issued for 
lopinavir/ritonavir, an Abbott medicine sold under the brand-name Kaletra.147  
Despite protests from foreign nations, as well as the Thai Pharmaceutical 
Research and Manufacturers Association (PReMA), the nation’s Health 
                                                                                                                   
 135 Id.  
 136 Id.  
 137 Id.  
 138 About MSF, MEDECINS SANS FRONTIERES, http://www.msf.org/en/about-msf (last visited 
Mar. 19, 2017). 
 139 See Thailand Issues Compulsory License for Patented AIDS Drug, supra note 103.  
 140 Id.  
 141 Id.  
 142 Id.  
 143 Id.  
 144 Id.  
 145 The Campaign for Use of Compulsory Licensing in Thailand, MAKE MEDICINES AFFORDABLE (Feb. 
18, 2015), http://makemedicinesaffordable.org/en/the-campaign-for-use-of-compulsory-licensin 
g-in-thailand/.  
 146 Id.  
 147 Id.  
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Minister chose another option and “signed the licenses and imported a generic 
version of Efavirenz from Indian Pharmaceutical company, Rambaxy.”148  
Various estimates predict that if the Abbott license had been signed, Kaletra 
would have saved Thailand up to $24 million per year.149 
Soon after being denied, Abbott Labs denied Thailand the ability to access 
Aluvia, another one of its brand-name HIV drugs.150  In opposition to the 
authorized license, Abbott withdrew all its “medications awaiting registration in 
addition to refusing to register any new pharmaceutical products in 
Thailand.”151  As a result of the American manufacturer’s actions, scores of 
HIV/AIDS activist groups and organizations rallied against the pharmaceutical 
industry’s suggested financial greed and uncooperative demeanor.152 
The world watched as protests were held, and demands were made by both 
parties.153  Despite the rising tensions, the events created a strong push towards 
the pro-generic camp’s initial goal of price reduction.154  Following the issuing of 
the Ranbaxy compulsory license, “Thai health authorities purchased a WHO pre-
qualified generic form of Efavirenz.”155  Ranbaxy offered the generic at a price of 
$20 per bottle, compared to Merck’s brand-name price tag of $43 per bottle.156 
Furthermore, the move resulted in Merck and Abbott reducing their prices 
to create competition with the Indian generic, with Merck offering to reduce its 
drug to $23 per bottle.157  While the offer was again rejected, it proved that the 
signing of the compulsory license played a large role in driving down the costs 
of patented medical necessities.158 
C.  CASE STUDY: PAICE-TOYOTA HYBRID LICENSING AND ROYALTY 
AGREEMENT 
In 2004, Paice, LLC. an automotive hybrid technology company,159 brought 
suit against Toyota, claiming the car manufacturer infringed upon three of the 
                                                                                                                   
 148 Id.  
 149 Id.  
 150 Id.  
 151 Id.  
 152 Id.  
 153 Id.  
 154 Id.  
 155 Id.  
 156 Id.  
 157 Id.  
 158 See id. (pointing to Abbot’s “plans to reduce the cost of Kaletra in Thailand and more than 
40 low- and –low-middle income countries for more than half”).  
 159 PAICE HYBRID, http://www.paicehybrid.com/ (last visited Jan. 10, 2017). 
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company’s patents.160  The Paice claim included two patents for the use of a 
clutch to provide torque to the vehicle’s engine,161 and one patent for a 
microprocessor and torque unit that “accepts torque input from both the ICE 
[internal combustion engine] and the electric motor.”162  These devices were 
installed in the Toyota Highlander and Prius, and the Lexus RX 400h vehicles.163  
In District Court, the jury found two patents were infringed upon, and 
offered a remedy in the form of a $25 per vehicle royalty on the infringing 
models, but the Court denied a permanent injunction.164  Upon appeal, the 
Federal Circuit Court held that there was no sufficient reasoning behind the 
royalty rate.165  As such, the case was remanded to the District Court to explain 
why a specific rate was appropriate.166  In a concurring opinion at the Federal 
Circuit, Justice Rader stated that the court should “require the district court to 
allow the parties an opportunity to set the ongoing royalty rate. . . .”167  The 
judge was of the opinion that a royalty was equivalent to a compulsory license if 
the parties never had the opportunity to negotiate outside court.168 
On remand from the Federal Circuit, the ongoing royalty rate was set at $98 
per vehicle.169  Then, much to the appeasement of Justice Rader’s call for 
private negotiation, Paice and Toyota settled in 2010.170  In the same year, Paice 
also engaged in private licensing negotiations with Ford.171 
According to Paice, the company now has “licensed all or part of its hybrid 
vehicle technology portfolio to Toyota, Hyundai/Kia, and Ford. . . .”172  These 
companies maintain approximately 90% of the market share for hybrid cars in 
the United States.173 
Although studied briefly, the three aforementioned case studies demonstrate 
the long and contentious process that can ensue when large companies engage 
in patent protection and litigation.  First, the WillowWood case demonstrates 
                                                                                                                   
 160 Paice LLC v. Toyota Motor Corp., 504 F.3d 1293, 1317 (Fed. Cir. 2007) (Rader, J., 
concurring).  
 161 Id. at 1299. 
 162 Id. at 1296. 
 163 Id. at 1299. 
 164 Id. at 1303. 
 165 Id. at 1316.  
 166 Id.  
 167 Id. at 1317. 
 168 Id.  
 169 Paice LLC v. Toyota Motor Corp., 609 F. Supp. 2d 620, 630 (E.D. Tx. 2009). 
 170 Licensing Agreements, PAICE HYBRID, http://www.paicehybrid.com/about/paices-work-with-
toyota-and-ford/ (last visited Feb. 20, 2017).  
 171 Id.  
 172 Id. 
 173 Id.  
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the oftentimes painstaking process that patent litigation can create.174  Second, 
the Thailand case study demonstrates the emergency context in which 
compulsory licensing can be defended under the WTO’s TRIPS Agreement.175  
More importantly, the case illustrates the downward pressure on price that 
compulsory licensing can bring, as competition attempts to flood a market, 
increasing supply.176  Finally, the Paice case study offers a taste of licensing 
agreements in the domestic market.177  Although the case dealt with hybrid 
vehicles, it similarly showcases the impact that the threat of court-appointed 
royalties may have on large corporations.178  As Justice Rader stated, “[C]alling a 
compulsory license an ‘ongoing royalty’ does not make it any less a compulsory 
license.”179  Fortunately, private negotiation and settlement is a possibility.   
III.  ANALYSIS 
Several alternatives will now be examined as potential price-reduction 
schemes to apply to the heavily-patented U.S. prosthetic market.  First, utilizing 
concepts from the Thailand case study, compulsory licensing will be analyzed as 
a tool through which the government can dramatically decrease the prices of 
prosthetic devices while also ensuring increased supply.  
Second, voluntary licensing will be examined as a lighter approach to 
overcoming patentability obstacles.  The Paice case will be utilized as support 
for voluntary negotiations and the private establishment of royalties between 
corporations, as opposed to those flowing via legal or governmental surrogate.   
Third, an alternative remedy will be put forth in which a government 
committee is set up to examine the patent and pricing models on high-tech 
prosthetic devices.  This model would follow in the footsteps of the 2016 
Senate Judiciary Committee request for investigations into the pricing structure 
of the EpiPen product.180 
Finally, the Note will attempt to analyze the future of the prosthetic industry 
if the suggested licensing schemes were proven futile.  In doing so, the growing 
                                                                                                                   
 174 See Ohio Willow Wood Co. v. Alps S., LLC, 813 F.3d at 1352 (stating, “This case marks the 
latest chapter in a long-roaming dispute . . .”). 
 175 See The Campaign for Use of Compulsory Licensing in Thailand, supra note 145. 
 176 See id.  
 177 See Paice, 504 F.3d at 1296. 
 178 See id. at 1316.  
 179 See id. at 1317 (Rader J., concurring).  
 180 Zachary Brennan, Updated: Senate Judiciary Committee Members Call for Investigation Into Price Increases 
of Mylan’s EpiPen, REGULATORY AFFAIRS PROFESSIONALS SOCIETY (Aug. 22, 2016), http://www. 
raps.org/Regulatory-Focus/News/2016/08/22/25670/Updated-Senate-Judiciary-Committee-Mem 
bers-Call-for-Investigation-Into-Price-Increases-of-Mylan’s-EpiPen/. 
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open-source and 3-D printing movements will be discussed as possible patent-
alternative, price-cutting mechanisms. 
A.  COMPULSORY LICENSING 
Compulsory licensing is one alternative to bypassing the monopoly rights 
given to patent owners.181  This form of licensing is created when the 
government forces the “holder of a right to grant the use of that right to 
other[s] upon the terms decided by the government.”182  In a traditional 
compulsory licensing scheme, the government pays royalties to the patent-
holding individual or corporation, as a quid pro quo for taking the patent 
without consent.183  
While compulsory licensing can be considered a form of government-
mandated piracy, it does have benefits.184  For instance, by having access to the 
intellectual property rights of advanced nations, developing countries are able to 
advance their own fields of science and technology.185  Furthermore, allowing for 
the reproduction of patented products may increase employment, and thus, have 
a positive economic impact.186  However, due to the patent system’s 
incentivization of research and development, many developed countries are 
opposed to any form of compulsory schemes.187  Moreover, in a pure compulsory 
licensing system, the royalties paid by the government are almost certainly unable 
to match the extra revenue that patent-holder would have made had the 
government not interfered with the exclusive right to the product in question.188 
In applying the scheme to prosthetics, take Ottobock’s revolutionary C-Leg 
for example.  The lower limb prosthetic has been fitted on over 60,000 qualified 
amputees since 1997.189  Furthermore, Ottobock has continued to update the 
C-Leg system with new patented additions.190  If compulsory licensing were 
applied to the prosthetic market, in theory, the government could force 
Ottobock to pass on its patents for the C-Leg prosthesis and componentry to 
                                                                                                                   
 181 Muhammad Zaheer Abbas, Pros and Cons of Compulsory Licensing, 3 INT’L J. SOC. SCI. & 
HUMANITY 254, 254–58 (2013). 
 182 Id. (quoting T. Jain, Compulsory Licenses Under TRIPS and Its Obligation for Member Countries, 8 
INT’L J. INTELL. PROP. RTS. 1 (2009)).  
 183 Id.  
 184 Id.  
 185 Id.  
 186 Id.  
 187 Id.  
 188 Id. at 255. 
 189 C-Leg 4, OTTOBOCK, http://www.ottobockus.com/media/local-media/prosthetics/lower-
limb/c-leg/files/cleg4brochure.pdf (last visited Mar. 21, 2017). 
 190 The C-Leg 4 Microprocessor Knee, OTTOBOCK, http://www.ottobock.co.uk/prosthetics/lower_ 
limb_prosthetics/prosthetic-product-systems/c-leg-4/ (last visited Mar. 21, 2017). 
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another manufacturer who could in turn produce an identical product for much 
less.  Ottobock would certainly have disdain for the government’s move, as it 
would rob the company of a great deal of potential revenue and market share.191  
However, the potential positive implications of such cannot be ignored.  
Like its competitors, Ottobock has faced the familiar burden of balancing 
technological advancement with accessibility and costs.  According to Miki 
Fairley of The O&P Edge, “As has been the case in other areas of O&P, 
reimbursement issues and gaps in research are impediments to technological 
advances and patient access.”192  Unfortunately, in this payment scheme, 
“payers often allow providers to only fit components that may actually decrease 
the patient’s safety and functionality.”193  Moreover, according to Brown 
University, the C-Leg prosthetic can cost $50,000, or, if fit with a prosthetic 
foot as well, $70,000 or more.194 
In the Thailand case study, the extreme prices of Western anti-retroviral drugs 
lead the government to issue a compulsory license for the importation of Merck’s 
generic drug.195  While that license did not come to fruition, it forced Merck to 
drop the price of its life-saving drug from $43 per bottle to $23 per bottle.196 
Compulsory licensing could create a similar price reduction in name-brand 
products, should Ottobock’s monopoly be taken away and given to smaller 
manufacturers.  As suggested in the International Journal of Social Science and 
Humanity, legal piracy “can ensure availability of needed goods and services to 
their citizens at affordable prices” in developing countries.197  This raises the 
question of whether compulsory licensing is able to address the similar problem 
of cost and supply here at home.  
Compulsory licensing is also likely to rouse loud critics as well.  According 
to Joanna Thurston, an IP attorney, “Allowing governments to intervene in 
patent matters in this way . . . is a dangerous precedent. . . .”198  At the forefront 
would be the argument that forced licensing deprives developers of their full 
property rights, thereby discouraging further investment in products in specific 
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 192 Miki Fairley, Microprocessor-Controlled Knees: Evolution of a Game Changer, O&P EDGE (June 
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markets.199  In the case of prosthetics, one fear is that by depriving Ottobock, 
Hanger, and other device manufacturers of their exclusive rights, it would 
discourage their future investment in life-changing limbs.  However, this 
concern would need to be weighed against other potential positives, including 
increased supply and decreased cost.   
Furthermore, there is the textual-based argument that the TRIPS agreement 
stated compulsory licensing should only be used in particular instances, 
including national emergencies.200  In rebuttal, while government-mandated 
licensing is likely to draw concern from skeptics, statistics point to the existence 
of a national health emergency that may justify the action.  Today, over 133 
million Americans have at least one chronic disease.201  These diseases, 
including diabetes, are disabling and bring a host of other health problems, 
including amputations.202  Every thirty seconds in the United States, a lower 
limb is “amputated as a consequence of diabetes.”203  While the magnitude of 
this health crisis issue can be debated, it is apparent that chronic diseases have a 
role in limb loss, and compulsory licensing is one way to combat the emergency 
by ensuring widespread access and lower costs.  
B.  VOLUNTARY LICENSING 
Voluntary licensing is another alternative method to overcoming 
patentability obstacles.  However, unlike compulsory licensing, the government 
is not involved in the negotiation or agreement process between the licensee 
and licensor.204  According to the World Health Organization (WHO), 
voluntary licensing agreements may “afford opportunities for significant cost-
containment.”205  Perhaps the most important factors in a successful voluntary 
licensing scheme are the specific terms of the license and the capacity of the 
licensee, or recipient of the patent.206  
In a traditional voluntary licensing agreement, the patent-holding company 
or individual may license their patent at their discretion, in an exclusive or non-
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exclusive fashion.207  The agreement may include any or all typical aspects of 
product development, including manufacturing, importation, and 
distribution.208  There are two common arrangements often made between 
licensees and licensors: one in which a licensee acts as an agent of the licensor 
patent-holder, and one in which the licensee is “free to set the terms of sale and 
distribution within a prescribed market or markets, contingent on payment of a 
royalty.”209  The WHO has deemed both arrangements viable options for price 
reduction on patented pharmaceutical products.210  As such, it is possible to 
foresee potential existing in the prosthetics industry as well. 
In the Paice patent infringement case study, the District Court threatened 
Toyota with a royalty payment to Paice at the rate of $98 per vehicle.211  
However, prior to remand, Justice Radar of the Federal Circuit had stated that 
the creation of an ongoing royalty simply created a compulsory license, unless 
the Court gave the litigants the opportunity to negotiate privately.212  
Fortunately for the parties involved, the threat of a court-made license resulted 
in a private voluntary license.213  
Similarly, in the realm of prosthetics limbs, voluntary licensing agreements 
could promote mutually beneficial outcomes while forcing prices downward.  
In the WillowWood infringement case,214 had the parties been able to reach a 
voluntary royalty rate for the patented componentry, millions of dollars of 
costly litigation and lost revenue may have been saved.   
Unfortunately, one downside to voluntary licensing is likely an inherent 
difficulty in forcing conversation amongst the current manufacturers of 
prosthetics.  The American Orthotic and Prosthetic Association (AOPA)215 has 
calculated that the U.S. O&P industry spends over $3.5 billion annually on 
patient services.216  Like many corporations, it may be difficult to talk industry 
giants into granting licenses on the technology they have so closely guarded.  
However, if the goal of the prosthetic movement is to push for cheaper, more 
accessible limbs, these conversations are pertinent.  
Furthermore, another key requirement in a voluntary licensing scheme is 
that the patent-holders have other corporations to bestow a license upon.  
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While courts could suggest voluntary licenses, as seen in Paice, LLC v. Toyota, 
the choice to grant a license to a smaller prosthetic company is a choice that 
could ideally be left up to consenting corporations in the free market.217  Using 
WillowWood as an example, one will find a plethora of smaller prosthetic 
suppliers, fitters, and manufacturers within a short distance of their primary 
production facility.218  Should WillowWood and its competitors wish to 
cooperate and play their role in supplying America’s amputee population with 
more accessible products, they need look no further than their backyard.  
C.  GOVERNMENT COMMITTEE 
The third approach to navigating the burdensome patentability obstacles in 
the prosthetic market again involves governmental interference.  However, unlike 
compulsory licensing, which may include government-induced production and 
royalty schemes, this approach is more economically laissez-faire while still 
allowing the government to bring attention to the national health crisis.  The 
recent epinephrine pricing controversy provides a fair illustration of the role the 
government can play in price-reduction without infringing on patents.219 
In 2016, as a direct result of the egregious EpiPen price surge, U.S. Senator 
Amy Klobuchar asked the Senate Judiciary Committee to investigate the 400% 
price increase of EpiPens.220  The Senator also called for the Federal Trade 
Commission to examine the alleged price gouging, and for the Commission to 
report to Congress on the cause of the price increase and their proposed 
solutions to “ ‘better protect consumers within 90 days.’ ”221  In agreement with 
the Senator, the administrator of the U.S Centers for Medicare and Medicaid 
Services stated, “We can make drug inflation more transparent & [sic] address 
unchecked increases without damaging innovation.”222  
In 2007, Mylan acquired the EpiPen, which cost just over $100.223  
However, by 2016, the cost had increased to approximately $600 per unit.224  
This price explosion has followed a common trend in the medical industry: 
dramatically raising prices just before a generic competitor enters the market.225  
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It is difficult, however, to determine the degree to which this same trend is 
happening in the prosthetic market.  
However, regardless of the differences in prosthetic limbs and epinephrine 
medication, as well as the variables that affect price for each, one thing remains 
clear: Congress and the U.S Department of Health and Human Services may 
similarly benefit from forming a commission to examine the pricing models for 
prosthetic limbs.  If this were to happen, not only could the publicity force 
major prosthetic manufacturers to decrease the cost of their patented limbs and 
componentry, the action could also have the effect of creating dialogue between 
major manufacturers and smaller companies with an interest in generic 
production, thus opening the door to voluntary licensing relationships.  
D.  STATUS QUO 
What if nothing were done by corporations or the courts to combat the 
extreme price of prosthetic technology and their accessibility-blocking patents?  
Should the status quo continue to exist without the enactment of any of the 
aforementioned alternatives, there may still be hope for cheaper and more 
accessible limbs via open source initiatives and 3-D printing.  
In 2005, Marine engineer Jonathan Kuniholm lost most of his right arm 
while on patrol in Iraq.226  After surgery, Kuniholm was fitted with a 
myoelectric arm at Walter Reed Military Hospital in Bethesda, Maryland.227  
However, he was not impressed with the design, which limited mobility and 
weight-bearing activities.228  Fortunately, as an engineer, Kuniholm and fellow 
Duke University students founded a non-profit known as The Open 
Prosthetics Project.229 
The Open Prosthetics Project “applies the ethical and intellectual property 
foundation of open-source software to the task of building better artificial 
limbs.”230  The Project allows anyone to publish and share their prosthetic 
projects in hopes of saving thousands of dollars and creating change in the 
prosthetics industry.231  Today, Open Prosthetics Project continues to share 
experimental designs that any member is able to download, alter in CAD 
software, and submit to 3-D printing companies.232 
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Kuniholm’s company is not the only one of its kind.  Other start-ups, 
including the Open Hand Project, realize the benefit that 3-D printing can 
create for amputees who otherwise have to pay upwards of six figures for new 
limbs.233  If these alternative methods continue to develop, there exists a very 
real possibility that they will also force prosthetic manufacturers to lower prices, 
or even follow in the foot-steps of Tesla and open source their own patents.234   
In order to be classified as open source by the Open Source Initiative, no 
royalty or sale fee may be collected.235  However, the official definition of the 
term makes no mention of restrictions on turning patents into open source 
products.  As Elon Musk, co-founder and CEO, has recently stated, patents 
now stifle progress and “receiving a patent really just meant that you bought a 
lottery ticket to a lawsuit. . . .”236  If the prosthetic industry also adopted this 
mindset, perhaps the future holds potential for collaboration between the 
growing generic sector and large corporate industry.  
IV.  CONCLUSION 
Despite a number of limitations in this Note, voluntary licensing is the best 
approach for the domestic prosthetic market to take in order to lower costs, 
increase supply, and avoid costly patent litigation. Much like the Paice case 
study, this pathway promotes mutually-beneficial outcomes without resorting to 
government licensing controls.   
Voluntary licensing also offers a more moderate approach to overhauling 
the prosthetic patent system.237  Compulsory licensing, on the other hand, 
would require a governmental (often judicial-based) mandate to allow for 
replication of patented-materials.238  As demonstrated in the Paice case, 
American courts may be more inclined to allow private companies to sort out 
their own licensing agreements before resorting to the judiciary.239 
While the primary goal of encouraging voluntary licensing agreements would 
be circumventing patenting practices to result in price-reduction and increased 
supply, voluntary agreements do not always guarantee lower costs.240  However, 
since most of these agreements are made at the discretion of the patent holder, 
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rather than the government, they are often used strategically; for instance, to 
foster market entry.241  If this methodology were used in the domestic 
prosthetics market, it could foster relationships between prosthetic behemoths 
and smaller regional-based manufacturing companies.  By granting licenses for 
production to smaller companies, the large corporations could ideally devote 
more time to R&D, while allowing for increased supply and greater competition 
in future markets.  Furthermore, down the road, such arrangements, contingent 
on royalties, “may allow for substantial price reductions.”242 
The future of the prosthetics industry is uncertain.  While there are signs of 
great promise, including revolutionary technologies like microprocessor-based 
limbs,243 there have also been controversies pertaining to Medicare, primary care 
providers, and licensed O&P practitioners.244  However, a number of case studies, 
some international, and other domestic, have attempted to demonstrate possible 
channels that the prosthetics industry can follow to alleviate price and supply 
pressures resulting from frivolous patents and lawsuits.  In alleviating this public 
health crisis, voluntary agreements are the ideal starting point for negotiations.  
Should this fail, judicial intervention may prove to be a necessity in order to 
swiftly and justly provide more accessible healthcare to millions of Americans.  
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